GPhA Creates Biosimilars Division; Will New Members Follow?

Pricing fight over hepatitis C treatments is positive ‘bellwether’ for biosimilars, Momenta CEO says.

MIAMI, Fla. – The Generic Pharmaceutical Association isn’t changing its name, but officials at the annual meeting here want to make it perfectly clear: They are focused on biosimilars.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America